Page 4 - Groupe Novasep News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jan 21 2021 Read 877 Times Thermo Fisher Scientific Inc and Groupe Novasep SAS have announced that Thermo Fisher has completed the acquisition of Henogen SA, Novasep’s viral vector manufacturing business in Belgium for approximately €725 million in cash. Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, Belgium, Novasep’s viral vector business offers more than 7,000 m2 of state-of-the-art clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of €80 million (or approximately $95 million).

Waals gewestUnited statesMichel lagardeMichel spagnolThermo fisher scientific incPharma servicesServices segmentThermo fisherLaboratory productsGroupe novasepExecutive vice presidentஒன்றுபட்டது மாநிலங்களில்மைக்கேல் லகார்ட்தெர்மோ மீனவர் அறிவியல் இன்க்பார்மா சேவைகள்சேவைகள் பிரிவு